Clinical Trial Details
| Trial ID: | L3379 |
| Source ID: | NCT03590626 |
| Associated Drug: | Dulaglutide |
| Title: | Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease |
| Acronym: | D-LIFT |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Non Alcoholic Fatty Liver Disease|Type2 Diabetes Mellitus |
| Interventions: | DRUG: Dulaglutide |
| Outcome Measures: | Primary: Change in liver fat, change in liver fat quantified by MRI-PDFF in colocalized regions of interest (ROI) within each of the nine liver segments, Baseline to 24 weeks | Secondary: Change in Biochemical Markers, change in serum AST levels, Basline to 24 weeks|Change in Fibroscan Parameters, Change in liver stiffness measurement (LSM) in kPa, Basline to 24 weeks|Change in Fibroscan Parameters, Change in Controlled Attenuation Parameter (CAP) in dB/m, Basline to 24 weeks|change in cardiometabolic markers, change in cardiometabolic markers namely IL-1, TNF-alpha, hs-CRP, leptin, adiponectin and homocysteine and fibrosis markers, Basline to 24 weeks|Change in Biochemical Markers, Change in serum ALT levels, Baseline to 24 weeks|Change in Biochemical Markers, change in serum GGT levels, Baseline to 24 weeks |
| Sponsor/Collaborators: | Sponsor: Medanta, The Medicity, India |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | |
| Enrollment: | 60 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT |
| Start Date: | 2019-01-01 |
| Completion Date: | 2020-02-18 |
| Results First Posted: | |
| Last Update Posted: | 2020-02-20 |
| Locations: | Division Of Endocrinology & Diabetes, Medanta The Medicity, Gurgaon, Haryana, 122001, India |
| URL: | https://clinicaltrials.gov/show/NCT03590626 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|